AVAVA MIRIA for Skin Conditions

This study is testing a device called AVAVA (a 1550nm Non-Ablative Fractional Laser) to treat various skin conditions like wrinkles, scars (including acne scars), active acne, and pigment issues (like sun spots or melasma). The main goal is to gather your feedback immediately after treatment through a questionnaire about your overall experience. Doctors will also evaluate improvements and side effects. You may be able to join if you are between 18 and 70 years old and have a skin condition that this laser can address. The current status of this study is unclear, but it plans to enroll about 200 participants.

Study design
This is an interventional study planning to enroll 200 participants. It is designed to treat a variety of skin conditions and collect patient feedback.
What's involved
You would receive treatment with the AVAVA device. You would complete a questionnaire immediately after treatment.
Compensation
Not stated in the trial record.
Follow-up
Your feedback will be collected immediately after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06868615

AVAVA MIRIA General Use

Recruiting
NAAges 18–70InterventionalTreatment
AVAVA, Inc.
~200 participants
Updated 2025-03-11 on ClinicalTrials.gov
What's tested:AVAVA

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Completion of Post-Treatment Subject Questionnaire
Measured over Immediate Post-Treatment
Acne
Acne Scars - Mixed Atrophic and Hypertrophic
Scars
Wrinkle
Pigment; Lesion
Skin Texture Disorder
1 sites across 1 states
Massachusetts1

Opens a ready-to-send draft in your own email app — review before sending.

  • Completion of Post-Treatment Subject QuestionnaireImmediate Post-Treatment

    Post-treatment questionnaire to evaluate the overall patient experience including descriptions of the treatment session and overall patient experience.